Table 3. Univariate and multivariate (corrected for age and gender) Cox regression analysis of clinical variables and long-term survival of patients with troponin elevation and non-acute coronary syndrome.
| Univariate Cox regression | Multivariate Cox Regression | |||
|---|---|---|---|---|
| HR (95% CI) | p Value | HR (95% CI) | p Value | |
| Age, y | 1.040 (1.017–1.063) | 0.001 | 1,030 (1,002–1,058) | 0.038 |
| Gender | 0.899 (0.540–1.499) | 0.684 | 0,807 (0,436–1,493) | 0.494 |
| CV risk factors | ||||
| Diabetes mellitus | 1.336 (0.783–2.277) | 0.288 | ||
| Hypertension | 1.245 (0.658–2.358) | 0.501 | ||
| Previous CAD | 1.067 (0.521–2.182) | 0.860 | ||
| Previous HF | 1.649 (0.967–2.812) | 0.066 | ||
| GFR, mL/(min⋅1.73 m2) | 0.992 (0.984–1.001) | 0.082 | ||
| Heart rate, bpm | 1.006 (0.997–1.014) | 0.193 | ||
| Previous Medication | ||||
| Antiplatelets | 1.867 (1.230–2.835) | 0.006 | 1,823 (1,105–3,006) | 0.019 |
| Beta-blockers | 0.806 (0.459–1.416) | 0.449 | ||
| ACE inhibitors | 0.689 (0.406–1.170) | 0.170 | ||
| MRA | 0.764 (0.262–2.226) | 0.611 | ||
| Statins | 1.017 (0.595–1.739) | 0.950 | ||
| ECG pattern | 1.162 (0.999–1.351) | 0.067 | ||
| Laboratory | ||||
| Isolated troponin elevation at the first evaluation | 0.533 (0.311–0.916) | 0.021 | 1.097 (0.378–3.180) | 0.865 |
| Isolated troponin elevation at the second evaluation | 0.528 (0.218–1.279) | 0.142 | ||
| % troponin elevation at two sequential evaluations | 1.000 (0.999–1.001) | 0.750 | ||
| Isolated troponin elevation at two sequential evaluations | 0. 239 (0.111–0.512) | <0.001 | 0.433 (0.196–0.958) | 0.039 |
| Hospitalization at index event | 3.782 (1.794–7.973) | <0.001 | 4.708 (1.652–13.423) | 0.004 |
95% CI: 95% confidence interval; CAD: coronary artery disease; HF: Heart failure; GFR: glomerular filtration rate according to MDRD equation; CK: creatine kinase; CK-MB: creatine kinase-MB; ACE inhibitor: angiotensin converting enzyme inhibitor; MRA: mineralocorticoid receptor antagonist; ECG: electrocardiogram.